Related Experiment Video
Updated: Sep 10, 2025
Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
Published on: November 30, 2016
Tissue MicroRNA Expression Signatures as Diagnostic Biomarkers and Predictors of Residual Disease Activity and
Tereza Deissova1,2, Dagmar Al Tukmachi1, Lenka Radova1
1Department of Biology, Faculty of Medicine and Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
Insights
MicroRNAs show promise as biomarkers for pediatric inflammatory bowel diseases (PIBD). This study identified specific microRNA signatures for diagnosing PIBD subtypes and predicting disease activity and relapse risk.
Area of Science:
- Gastroenterology
- Molecular Biology
- Pediatrics
Background:
- Pediatric inflammatory bowel diseases (PIBD), including Crohn's disease (pCD) and ulcerative colitis (pUC), require novel biomarkers for improved diagnosis and treatment.
- MicroRNAs (miRNAs) are implicated in PIBD pathogenesis and are being investigated for their diagnostic and prognostic utility.
Purpose of the Study:
- To investigate the diagnostic potential of microRNAs in distinguishing PIBD subtypes from non-IBD controls.
- To assess the prognostic value of microRNAs in predicting disease activity and relapse risk in pediatric IBD patients.
Main Methods:
- Prospective study with retrospective validation involving 119 PIBD patients and 39 controls.
- Small RNA sequencing of gut biopsies followed by RT-qPCR validation of candidate miRNAs.
- Logistic regression analysis to develop diagnostic and prognostic miRNA expression signatures.
Main Results:
- A 5-miRNA signature accurately diagnosed pCD (96.49%) and a 2-miRNA signature diagnosed pUC (100%) versus controls.
- A distinct miRNA signature differentiated pCD from pUC (83.54%) and predicted residual disease activity (100%) and relapse risk (84.21%) in pCD patients.
Conclusions:
- Tissue microRNA expression signatures possess significant diagnostic and prognostic potential for PIBD.
- These miRNA signatures can aid in stratifying disease severity and risk, enabling personalized management strategies for pediatric IBD.
Background:
Identifying novel diagnostic and prognostic biomarkers for pediatric inflammatory bowel diseases (PIBD), including Crohn's disease (pCD) and ulcerative colitis (pUC), is essential for enhancing treatment outcomes. MicroRNAs (miRNAs) have been recognized for their broader relevance in PIBD pathogenesis. This study investigates their diagnostic potential and clinical utility in PIBD.
Methods:
This prospective, monocentric study, with retrospective validation, involved 119 PIBD patients (58 pCD, 61 pUC) and 39 non-IBD controls. Small RNA next-generation sequencing was performed on fresh-frozen gut biopsies, targeting histopathologically confirmed inflamed areas. Twenty-five dysregulated miRNA candidates were validated via RT-qPCR in formalin-fixed, paraffin-embedded gut biopsies. Logistic regression was used to establish diagnostic and prognostic miRNA expression signatures.
Results:
A diagnostic signature of 5 miRNAs (miR-223-3p, miR-34a-5p, miR-194-5p, miR-215-5p, miR-338-3p) distinguished pCD from non-IBD with 96.49% accuracy. Two miRNAs (miR-223-3p, miR-194-5p) differentiated pUC from non-IBD with 100% accuracy, and miR-215-5p distinguished pCD from pUC specimens with 83.54% accuracy. For treatment-naïve pCD patients, 7 miRNAs predicted residual disease activity at 3 months with 100% accuracy. Additionally, a distinct signature predicted the risk of relapse within 12 months with an accuracy of 84.21%.
Conclusions:
In this study, we have established tissue miRNA expression signatures with significant diagnostic and prognostic potential for use in PIBD. These findings aid in stratifying disease severity and risk, paving the way for more precise and personalized management of pediatric IBD.
